TaiMed Biologics (4147) - Total Liabilities
Based on the latest financial reports, TaiMed Biologics (4147) has total liabilities worth NT$953.05 Million TWD (≈ $30.03 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore TaiMed Biologics net asset momentum to track the company's year-over-year net asset growth rate.
TaiMed Biologics - Total Liabilities Trend (2009–2025)
This chart illustrates how TaiMed Biologics's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of TaiMed Biologics to measure how efficiently the company converts operating cash flow to free cash.
TaiMed Biologics Competitors by Total Liabilities
The table below lists competitors of TaiMed Biologics ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Anhui Gourgen Traffic Construction Co Ltd
SHG:603815
|
China | CN¥7.49 Billion |
|
Zhejiang Huada New Materials Co Ltd
SHG:605158
|
China | CN¥5.93 Billion |
|
Forth Corporation Public Company Limited
BK:FORTH
|
Thailand | ฿8.93 Billion |
|
Zhejiang Risun Intelligent Technology Co. Ltd. A
SHG:688215
|
China | CN¥668.20 Million |
|
YG Entertainment Inc
KQ:122870
|
Korea | ₩209.26 Billion |
|
BlackRock Health Sciences Trust
NYSE:BME
|
USA | $1.83 Million |
|
Lanzhou Greatwall Electrical Co Ltd
SHG:600192
|
China | CN¥3.62 Billion |
|
Almendral
SN:ALMENDRAL
|
Chile | CL$3.83 Trillion |
Liability Composition Analysis (2009–2025)
This chart breaks down TaiMed Biologics's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 4147 company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how TaiMed Biologics's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for TaiMed Biologics (2009–2025)
The table below shows the annual total liabilities of TaiMed Biologics from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$953.05 Million ≈ $30.03 Million |
-2.39% |
| 2024-12-31 | NT$976.34 Million ≈ $30.76 Million |
-26.47% |
| 2023-12-31 | NT$1.33 Billion ≈ $41.83 Million |
-4.21% |
| 2022-12-31 | NT$1.39 Billion ≈ $43.67 Million |
-16.96% |
| 2021-12-31 | NT$1.67 Billion ≈ $52.59 Million |
-6.25% |
| 2020-12-31 | NT$1.78 Billion ≈ $56.09 Million |
+55.58% |
| 2019-12-31 | NT$1.14 Billion ≈ $36.05 Million |
+61.05% |
| 2018-12-31 | NT$710.55 Million ≈ $22.39 Million |
+237.22% |
| 2017-12-31 | NT$210.71 Million ≈ $6.64 Million |
+139.48% |
| 2016-12-31 | NT$87.99 Million ≈ $2.77 Million |
+230.38% |
| 2015-12-31 | NT$26.63 Million ≈ $839.05K |
-47.11% |
| 2014-12-31 | NT$50.35 Million ≈ $1.59 Million |
-11.66% |
| 2013-12-31 | NT$56.99 Million ≈ $1.80 Million |
+300.43% |
| 2012-12-31 | NT$14.23 Million ≈ $448.42K |
-6.04% |
| 2011-12-31 | NT$15.15 Million ≈ $477.25K |
-10.24% |
| 2010-12-31 | NT$16.88 Million ≈ $531.72K |
-11.55% |
| 2009-12-31 | NT$19.08 Million ≈ $601.16K |
-- |
About TaiMed Biologics
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinica… Read more